{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:28:32Z","timestamp":1780514912522,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":185,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100832","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T16:26:04Z","timestamp":1720542364000},"page":"100832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion\u2013mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study"],"prefix":"10.1016","volume":"40","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio A.","family":"Schioppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo H.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Rahhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sermon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ghilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Thayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthiv","family":"Mahadevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2024.100832_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ctarc.2024.100832_bib0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11523-022-00868-z","article-title":"Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis","volume":"17","author":"Van Sanden","year":"2022","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ctarc.2024.100832_bib0003","series-title":"Proceedings of the European Lung Cancer Congress (ELCC)","article-title":"1P Real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion","author":"Viteri","year":"2021"},{"key":"10.1016\/j.ctarc.2024.100832_bib0004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2024.100832_bib0005","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2024.100832_bib0006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cllc.2022.07.007","article-title":"Comparative clinical outcomes between EGFR Ex20ins and wildtype NSCLC treated with immune checkpoint inhibitors","volume":"23","author":"Girard","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2024.100832_bib0007","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.jtho.2019.08.1446","article-title":"P2.01-103 Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations","volume":"14","author":"Dersarkissian","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2024.100832_bib0008","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2024.100832_bib0009","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1200\/jco.2012.30.15_suppl.7577","article-title":"The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second\/third line","volume":"30","author":"Grossi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2024.100832_bib0010","series-title":"Rybrevant\u00ae (Amivantamab-Vmjw) Injection, for Intravenous Use [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.ctarc.2024.100832_bib0011","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1200\/JCO.2020.38.15_suppl.9580","article-title":"Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions","volume":"38","author":"Horn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2024.100832_bib0012","doi-asserted-by":"crossref","first-page":"S871","DOI":"10.1016\/j.annonc.2020.08.1676","article-title":"1362P Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): a meta-analysis","volume":"31","author":"Tomaras","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2024.100832_bib0013","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2022.03.005","article-title":"Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy","volume":"168","author":"Minchom","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2024.100832_bib0014","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12325-022-02408-7","article-title":"An adjusted treatment comparison comparing amivantamab versus real-world clinical practice in Europe and the United States for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations","volume":"40","author":"Chouaid","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ctarc.2024.100832_bib0015","doi-asserted-by":"crossref","first-page":"S1062","DOI":"10.1016\/j.annonc.2022.07.1242","volume":"33","author":"Girard","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T03:16:10Z","timestamp":1728357370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294224000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":15,"alternative-id":["S2468294224000443"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100832","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion\u2013mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100832"}}